Literature DB >> 12660545

Hyperlipidemia in HIV-infected patients: the protective effect of hepatitis C virus co-infection.

Julio Collazos1, José Mayo, Sofía Ibarra, Juan Cazallas.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12660545     DOI: 10.1097/01.aids.0000060344.12269.9e

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  6 in total

Review 1.  Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients.

Authors:  Roger Bedimo; Oladapo Abodunde
Journal:  Curr HIV/AIDS Rep       Date:  2016-12       Impact factor: 5.071

2.  Evaluation of Statin Eligibility, Prescribing Practices, and Therapeutic Responses Using ATP III, ACC/AHA, and NLA Dyslipidemia Treatment Guidelines in a Large Urban Cohort of HIV-Infected Outpatients.

Authors:  Matthew E Levy; Alan E Greenberg; Manya Magnus; Naji Younes; Amanda Castel
Journal:  AIDS Patient Care STDS       Date:  2018-02       Impact factor: 5.078

3.  Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care.

Authors:  Heidi M Crane; Carl Grunfeld; James H Willig; Michael J Mugavero; Stephen Van Rompaey; Richard Moore; Benigno Rodriguez; Betsy J Feldman; Michael M Lederman; Michael S Saag; Mari M Kitahata
Journal:  AIDS       Date:  2011-01-14       Impact factor: 4.177

4.  Immunosuppression and HIV Viremia Associated with More Atherogenic Lipid Profile in Older People with HIV.

Authors:  Matthew E Levy; Alan E Greenberg; Manya Magnus; Naji Younes; Amanda Castel
Journal:  AIDS Res Hum Retroviruses       Date:  2018-11-27       Impact factor: 2.205

5.  Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men.

Authors:  Michelle Floris-Moore; Andrea A Howard; Yungtai Lo; Ellie E Schoenbaum; Julia H Arnsten; Robert S Klein
Journal:  AIDS Patient Care STDS       Date:  2007-07       Impact factor: 5.078

Review 6.  Challenges in the management of HIV and hepatitis C virus co-infection.

Authors:  Winston Lee; Douglas Dieterich
Journal:  Drugs       Date:  2004       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.